UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia

Haematologica (Roma), 2019-04, Vol.104 (4), p.700

2019

Volltextzugriff (PDF)

A feasibility and acceptability study of an adaptation of the Mindful Self-Compassion program for adult cancer patients

Palliative & supportive care, 2020-04, Vol.18 (2), p.130-140

2020

Volltextzugriff (PDF)

Complete remission of Waldenström's associated generalized crystal-storing histiocytosis of IgM lambda subtype with bortezomib-based combination chemotherapy

Leukemia & lymphoma, 2015-11, Vol.56 (11), p.3233-3235

2015

Volltextzugriff (PDF)

Favorable outcomes of DDX41 ‐mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide

EJHaem, 2023-11, Vol.4 (4), p.1212-1215

2023

Volltextzugriff (PDF)

Tumor Lysis Syndrome Early After Treatment with Bortezomib for Multiple Myeloma

Pharmacotherapy, 2006-08, Vol.26 (8), p.1205-1206

2006

Volltextzugriff (PDF)

Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine

European journal of haematology, 2011-08, Vol.87 (2), p.186-188

2011

Volltextzugriff (PDF)

Favorable Outcomes of DDX41-Mutated MDS and Low Blast Count AML Treated with Azacitidine with or without Lenalidomide (ALLG MDS4 Trial)

Blood, 2022-11, Vol.140 (Supplement 1), p.4090-4091

2022

Volltextzugriff (PDF)

Transfusion reactions in myelodysplastic neoplasms (MDNs): a retrospective cohort study

Pathology, 2024-02, Vol.56, p.S38

2024

Volltextzugriff (PDF)

Epigenetic studies guiding therapy

Pathology, 2011, Vol.43, p.S36-S36

Kenealy, Melita

2011

Volltextzugriff (PDF)

Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia

Leukemia & lymphoma, 2022-02, Vol.63 (3), p.676-683

2022

Volltextzugriff (PDF)

Dysregulation of immune cell and cytokine signalling correlates with clinical outcomes in myelodysplastic syndrome (MDS)

European journal of haematology, 2022-04, Vol.108 (4), p.342-353

2022

Volltextzugriff (PDF)

Abstract 1548: Genetic biomarkers predict clinical response and survival in myelodysplasia

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1548-1548

2018

Volltextzugriff (PDF)

3178 – LONGITUDINAL DRUG INCORPORATION, CLONAL COMPOSITION, AND DNA METHYLATION DYNAMICS IN MDS/CMML PATIENTS TREATED WITH AZA

Experimental hematology, 2024-08, Vol.137, p.104498, Article 104498

2024

Volltextzugriff (PDF)

In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial

Blood, 2022-11, Vol.140 (Supplement 1), p.6927-6929

2022

Volltextzugriff (PDF)

Treatment of chronic myelomonocytic leukemia with azacitidine

Leukemia & lymphoma, 2013-04, Vol.54 (4), p.878-880

2013

Volltextzugriff (PDF)

Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study

Leukemia & lymphoma, 2019-07, Vol.60 (9), p.2122-2133

2019

Volltextzugriff (PDF)

Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML)

Leukemia & lymphoma, 2017-02, Vol.58 (2), p.298-307

2017

Volltextzugriff (PDF)

Final Analysis of a Phase II Study of Intrapatient Dose-Escalation of Eltrombopag in Patients Receiving Azacitidine for Myelodysplasia/AML

Blood, 2014-12, Vol.124 (21), p.4657-4657

2014

Volltextzugriff (PDF)

Treatment-related myelodysplasia following fludarabine combination chemotherapy

Haematologica (Roma), 2006-11, Vol.91 (11), p.1546-1550

2006

Volltextzugriff (PDF)

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents

Expert review of anticancer therapy, 2007-10, Vol.7 (10), p.1439-1449

2007

Volltextzugriff (PDF)

Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine: Letter to the editor

European journal of haematology, 2011-08, Vol.87 (2), p.186-188

2011

Volltextzugriff (PDF)

IgA nephropathy associated with cutaneous T cell lymphoma

Leukemia & lymphoma, 2009-12, Vol.50 (12), p.2083-2085

2009

Volltextzugriff (PDF)

The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS)

Blood, 2009-11, Vol.114 (22), p.1749-1749

2009

Volltextzugriff (PDF)

Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy

Leukemia & lymphoma, 2006-09, Vol.47 (9), p.1813-1817

2006

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(26)
Berichte
(3)

Sprache

Englisch
(29)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(15)
Science & Technology
(15)
Hematology
(12)
Humans
(12)
Female
(9)
Aged
(8)
Male
(8)
Middle Aged
(8)
Oncology
(8)
Adult
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Myelodysplastic Syndrome
(4)
Treatment Outcome
(4)
Aged, 80 And Over
(3)
Leukemia, Myeloid, Acute - Drug Therapy
(3)
Myelodysplastic Syndromes - Drug Therapy
(3)
Acute Myeloid Leukemia
(2)
Azacitidine
(2)
Azacitidine - Administration & Dosage
(2)
Azacitidine - Adverse Effects
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia

A feasibility and acceptability study of an adaptation of the Mindful Self-Compassion program for adult cancer patients

Complete remission of Waldenström's associated generalized crystal-storing histiocytosis of IgM lambda subtype with bortezomib-based combination chemotherapy

Favorable outcomes of DDX41 ‐mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide

Tumor Lysis Syndrome Early After Treatment with Bortezomib for Multiple Myeloma

Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine

Favorable Outcomes of DDX41-Mutated MDS and Low Blast Count AML Treated with Azacitidine with or without Lenalidomide (ALLG MDS4 Trial)

Transfusion reactions in myelodysplastic neoplasms (MDNs): a retrospective cohort study

Epigenetic studies guiding therapy

Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia

Dysregulation of immune cell and cytokine signalling correlates with clinical outcomes in myelodysplastic syndrome (MDS)

Abstract 1548: Genetic biomarkers predict clinical response and survival in myelodysplasia

3178 – LONGITUDINAL DRUG INCORPORATION, CLONAL COMPOSITION, AND DNA METHYLATION DYNAMICS IN MDS/CMML PATIENTS TREATED WITH AZA

In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial

Treatment of chronic myelomonocytic leukemia with azacitidine

Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study

In Vivo Assessment of Intracellular Dynamics Comparing Injection Versus Oral Azacitidine in a Phase IIb Investigator Initiated Clinical Trial

Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML)

Final Analysis of a Phase II Study of Intrapatient Dose-Escalation of Eltrombopag in Patients Receiving Azacitidine for Myelodysplasia/AML

Treatment-related myelodysplasia following fludarabine combination chemotherapy

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents

Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine: Letter to the editor

IgA nephropathy associated with cutaneous T cell lymphoma

The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS)

Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy

Suchergebnisse filtern